Date published: 2026-1-9

1-800-457-3801

SCBT Portrait Logo
Seach Input

PMEPA1 Activators

PMEPA1 Activators comprise a chemical class designed to modulate the activity of the protein Prostate Transmembrane Protein, Androgen Induced 1 (PMEPA1). PMEPA1 is implicated in various cellular processes including signal transduction, protein degradation, and the regulation of transcription factors, such as the androgen receptor. The protein is known to be involved in the ubiquitination pathway, targeting specific proteins for degradation by the proteasome.

The activation of PMEPA1 by these chemicals can be achieved through direct or indirect means. Direct activators may bind to PMEPA1 and enhance its stability or its interaction with other proteins, such as NEDD4, a ubiquitin ligase that PMEPA1 is known to interact with, thereby potentially increasing the ubiquitination and subsequent degradation of target proteins. These activators could also influence the post-translational modifications of PMEPA1, modifying its activity or the spectrum of its protein interactions. Indirect PMEPA1 activators may affect the signaling pathways that control the expression of the PMEPA1 gene, leading to increased production of the protein. They could also modulate the activity of proteins that interact with PMEPA1, thereby altering its function. For example, they could inhibit the degradation of PMEPA1, resulting in enhanced levels of the active protein, or they could increase the transcriptional activity of factors that upregulate PMEPA1 expression. The exploration of PMEPA1 Activators is important in research as it contributes to the understanding of protein regulation via the ubiquitin-proteasome system. PMEPA1's role in this system makes it a key player in the control of protein turnover, a fundamental aspect of cellular homeostasis. By studying PMEPA1 Activators, scientists can gain insights into the mechanisms that control protein degradation and the complex regulatory networks that ensure cellular proteins are precisely expressed and maintained at the correct levels.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Forskolin

66575-29-9sc-3562
sc-3562A
sc-3562B
sc-3562C
sc-3562D
5 mg
50 mg
1 g
2 g
5 g
$78.00
$153.00
$740.00
$1413.00
$2091.00
73
(3)

Adenylyl cyclase activator that increases cAMP, leading to PKA activation which can phosphorylate proteins in signaling pathways where PMEPA1 is a component, therefore enhancing PMEPA1 activity indirectly.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

MEK inhibitor that indirectly enhances PMEPA1 activity by altering the ERK/MAPK signaling pathway in which PMEPA1 is a regulatory factor.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

PI3K inhibitor that modifies downstream Akt signaling, potentially enhancing PMEPA1 activity by affecting its role in the pathway.

GW 5074

220904-83-6sc-200639
sc-200639A
5 mg
25 mg
$106.00
$417.00
10
(1)

Raf kinase inhibitor that can influence PMEPA1 activity through modulation of the MAPK/ERK pathway, in which PMEPA1 has a functional role.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

JNK inhibitor that could enhance PMEPA1 activity by affecting the JNK signaling pathway that intersects with PMEPA1's regulatory functions.

AICAR

2627-69-2sc-200659
sc-200659A
sc-200659B
50 mg
250 mg
1 g
$65.00
$280.00
$400.00
48
(2)

AMPK activator that can enhance PMEPA1 activity by modulating cellular energy pathways that intersect with PMEPA1's role in the cell.

Zoledronic acid, anhydrous

118072-93-8sc-364663
sc-364663A
25 mg
100 mg
$92.00
$256.00
5
(0)

Bisphosphonate that inhibits farnesyl pyrophosphate synthase, potentially enhancing PMEPA1 activity due to PMEPA1's involvement in bone metabolism and response to bisphosphonates.

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$152.00
$479.00
$632.00
$1223.00
$2132.00
33
(3)

Histone deacetylase inhibitor that can enhance PMEPA1 activity indirectly by altering chromatin structure and affecting transcriptional programs involving PMEPA1.